ELAVL4

Across TCGA pan-cancer cohorts, ELAVL4 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated ELAVL4 data layer compared with 6 for mutation status.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ELAVL4 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated ELAVL4 expression acts as an unfavorable survival marker, although some lineages such as SCLC and HNSC show a favorable association.

SCLC, LIHC, and HNSC are the cancer types where ELAVL4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.578	0.273	<.001	95	view →
LIHC	OS	Tertile	All	0.669	0.853	.002	60	view →
HNSC	DFS	Median	All	0.764	0.653	.002	47	view →
SKCM	OS	Median	All	0.415	0.268	.001	36	view →
LGG	DFS	Median	All	0.871	0.789	<.001	35	view →
CESC	DFS	Median	All	0.822	0.652	<.001	32	view →
LUAD	OS	Median	II,III,IV	0.548	0.337	.006	32	view →
PAAD	DFS	Median	All	0.364	0.202	.006	32	view →
ACC	DFS	Tertile	All	0.864	0.538	.009	20	view →
MESO	OS	Quartile	All	0.451	0.741	.004	13	view →
PCPG	DFS	Median	All	1.000	0.809	.002	13	view →
UVM	DFS	Median	All	0.356	0.532	.030	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

ELAVL4–SCLC (DFS)

Open the SCLC breakdown →